Novel coronavirus disease 2019 (COVID-19) has been associated with an increased risk of arterial and venous thromboembolic (VTE) diseases. However, there is a limited amount of data regarding the prevention and management of VTE in severe hospitalized COVID-19 patients. ⋯ In this article, we review currently available clinical data, and mechanisms for COVID-associated coagulopathy, and propose algorithms for screening, prevention (including extended-duration prophylaxis), and treatment of these patients. Although these recommendations are subject to change given rapidly evolving data, we provide a framework that can guide clinicians in managing thrombotic complications in this challenging condition.
Madan Raj Aryal, Rohit Gosain, Anthony Donato, Ranjan Pathak, Vijaya Raj Bhatt, Anjan Katel, and Peter Kouides.
Department of Medicine, Roswell Park Comprehensive Cancer Center, University at Buffalo, Elm and Carlton Streets, Buffalo, NY, 14263, USA. madan.aryal@roswellpark.org.
Curr Cardiol Rep. 2020 Jun 11; 22 (7): 52.
Purpose Of ReviewNovel coronavirus disease 2019 (COVID-19) has been associated with an increased risk of arterial and venous thromboembolic (VTE) diseases. However, there is a limited amount of data regarding the prevention and management of VTE in severe hospitalized COVID-19 patients.Recent FindingsIn this article, we review currently available clinical data, and mechanisms for COVID-associated coagulopathy, and propose algorithms for screening, prevention (including extended-duration prophylaxis), and treatment of these patients. Although these recommendations are subject to change given rapidly evolving data, we provide a framework that can guide clinicians in managing thrombotic complications in this challenging condition.